Legend Biotech (NASDAQ: LEGN)
Legend Biotech Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Legend Biotech Company Info
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
News & Analysis
What Companies Does Johnson & Johnson Own?
After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?
Legend's cell therapy seems like it's a winner, but it might be priced in already.
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.
Why Legend Biotech's Shares Jumped 11.8% on Wednesday
Investors, on second glance, might think the company's stock offering is a good idea.
2 Biotechs With Recent FDA Approvals to Hold for the Next Decade
With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.
Why Legend Biotech Shares Plummeted 17.6% Wednesday
The clinical-stage biotech company's stock dropped more than $4 a share from its Tuesday close.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.